|
1
|
Scher HI, Steineck G and Kelly WK:
Hormone-refractory (D3) prostate cancer: refining the concept.
Urology. 46:142–148. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fakih M, Johnson CS and Trump DL:
Glucocorticoids and treatment of prostate cancer: a preclinical and
clinical review. Urology. 60:553–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nishimura K, Nonomura N, Yasunaga Y, et
al: Low doses of oral dexamethasone for hormone-refractory prostate
carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang C, Mattern J, Haferkamp A, et al:
Corticosteroid-induced chemotherapy resistance in urological
cancers. Cancer Biol Ther. 5:59–64. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weitzman AL, Shelton G, Zuech N, et al:
Dexamethasone does not significantly contribute to the response
rate of docetaxel and estramustine in androgen-independent prostate
cancer. J Urol. 163:834–837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang CY, Walther PJ and McDonnell DP:
Glucocorticoids manifest androgenic activity in a cell line derived
from a metastatic prostate cancer. Cancer Res. 61:8712–8717.
2001.PubMed/NCBI
|
|
7
|
Reyes-Moreno C, Frenette G, Boulanger J,
Lavergne E, Govindan MV and Koutsilieris M: Mediation of
glucocorticoid receptor function by transforming growth factor beta
I expression in human PC-3 prostate cancer cells. Prostate.
26:260–269. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM
and Xu H: Dexamethasone suppresses DU145 cell proliferation and
cell cycle through inhibition of the extracellular signal-regulated
kinase 1/2 pathway and cyclin D1 expression. Asian J Androl.
10:635–641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akakura K, Akimoto S, Ohki T and Shimazaki
J: Antiandrogen withdrawal syndrome in prostate cancer after
treatment with steroidal antiandrogen chlormadinone acetate.
Urology. 45:700–705. 1995. View Article : Google Scholar
|
|
10
|
Soloway MS, Hardeman SW, Hickey D, et al:
Stratification of patients with metastatic prostate cancer based on
extent of disease on initial bone scan. Cancer. 61:195–202. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lam JS, Leppert JT, Vemulapalli SN,
Shvarts O and Belldegrun AS: Secondary hormonal therapy for
advanced prostate cancer. J Urol. 175:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saad F, Gleason DM, Murray R, et al:
Long-term efficacy of zoledronic acid for the prevention of
skeletal complications in patients with metastatic
hormone-refractory prostate cancer. J Natl Cancer Inst. 96:879–882.
2004. View Article : Google Scholar
|
|
13
|
Akakura K, Suzuki H, Ueda T, et al:
Possible mechanism of dexamethasone therapy for prostate cancer:
suppression of circulating level of interleukin-6. Prostate.
56:106–109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okamoto M, Lee C and Oyasu R:
Interleukin-6 as a paracrine and autocrine growth factor in human
prostatic carcinoma cells in vitro. Cancer Res. 57:141–146.
1997.PubMed/NCBI
|
|
15
|
Chung TD, Yu JJ, Spiotto MT, Bartkowski M
and Simons JW: Characterization of the role of IL-6 in the
progression of prostate cancer. Prostate. 38:199–207. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lou W, Ni Z, Dyer K, Tweardy DJ and Gao
AC: Interleukin-6 induces prostate cancer cell growth accompanied
by activation of stat3 signaling pathway. Prostate. 42:239–242.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hobisch A, Eder IE, Putz T, et al:
Interleukin-6 regulates prostate-specific protein expression in
prostate carcinoma cells by activation of the androgen receptor.
Cancer Res. 58:4640–4645. 1998.PubMed/NCBI
|
|
18
|
Chen T, Wang LH and Farrar WL: Interleukin
6 activates androgen receptor-mediated gene expression through a
signal transducer and activator of transcription 3-dependent
pathway in LNCaP prostate cancer cells. Cancer Res. 60:2132–2135.
2000.
|
|
19
|
Ueda T, Bruchovsky N and Sadar MD:
Activation of the androgen receptor N-terminal domain by
interleukin-6 via MAPK and STAT3 signal transduction pathways. J
Biol Chem. 277:7076–7085. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tannock IF, de Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petrylak DP, Tangen CM, Hussain MH, et al:
Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimojo M, Hiroi N, Yakushiji F, Ueshiba
H, Yamaguchi N and Miyachi Y: Differences in down-regulation of
glucocorticoid receptor mRNA by cortisol, prednisolone and
dexamethasone in HeLa cells. Endocr J. 42:629–636. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelly WK, Curley T, Leibretz C, Dnistrian
A, Schwartz M and Scher HI: Prospective evaluation of
hydrocortisone and suramin in patients with androgen-independent
prostate cancer. J Clin Oncol. 13:2208–2213. 1995.PubMed/NCBI
|
|
24
|
Kantoff PW, Halabi S, Conaway M, et al:
Hydrocortisone with or without mitoxantrone in men with
hormone-refractory prostate cancer: results of the cancer and
leukemia group B 9182 study. J Clin Oncol. 17:2506–2513.
1999.PubMed/NCBI
|
|
25
|
Tannock I, Gospodarowicz M, Meakin W,
Panzarella T, Stewart L and Rider W: Treatment of metastatic
prostatic cancer with low-dose prednisone: evaluation of pain and
quality of life as pragmatic indices of response. J Clin Oncol.
7:590–597. 1989.PubMed/NCBI
|
|
26
|
Sartor O, Weinberger M, Moore A, Li A and
Figg WD: Effect of prednisone on prostate-specific antigen in
patients with hormone-refractory prostate cancer. Urology.
52:252–256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fuse H, Nozaki T, Fujiuchi Y, Mizuno I,
Nagakawa O and Okumura A: Treatment with prednisolone of
hormone-refractory prostate cancer. Arch Androl. 52:35–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nishiyama T and Terunuma M:
Hormone/antihormone withdrawal and dexamethasone for
hormone-refractory prostate cancer. Int J Urol. 5:44–47. 1998.
View Article : Google Scholar : PubMed/NCBI
|
